Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Emicizumab in Hemophilia A: NCT04690322 Clinical Landscape Report 2026
16 October 2026
NCT04690322 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ketorolac in Anemia, Sickle Cell: CTRI/2021/01/030300 Clinical Landscape Report 2026
16 October 2026
CTRI/2021/01/030300 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MET-409 in Diabetes Mellitus, Type 2: NCT04702490 Clinical Landscape Report 2026
16 October 2026
NCT04702490 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FM-101 in Metabolic Dysfunction Associated Steatohepatitis: NCT04710524 Clinical Landscape Report 2026
16 October 2026
NCT04710524 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Treprostinil in Idiopathic Pulmonary Fibrosis: NCT04708782 Clinical Landscape Report 2026
16 October 2026
NCT04708782 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HU-6 in Metabolic Dysfunction Associated Steatohepatitis: NCT04709913 Clinical Landscape Report 2026
16 October 2026
NCT04709913 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Efgartigimod/Hyaluronidase in Myasthenia Gravis: NCT04735432 Clinical Landscape Report 2026
16 October 2026
NCT04735432 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NIP-292 in Idiopathic Pulmonary Fibrosis: NCT04720443 Clinical Landscape Report 2026
16 October 2026
NCT04720443 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zalfermin in Metabolic Dysfunction Associated Steatohepatitis: NCT04722653 Clinical Landscape Report 2026
16 October 2026
NCT04722653 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Efanesoctocog alfa in Hemophilia A: NCT04759131 Clinical Landscape Report 2026
16 October 2026
NCT04759131 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Human normal immunoglobulin(Takeda) in Myasthenia Gravis: NCT04728425 Clinical Landscape Report 2026
16 October 2026
NCT04728425 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efmoroctocog alfa(Sobi Analytics) in Hemophilia A: NCT04728217 Clinical Landscape Report 2026
16 October 2026
NCT04728217 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.